Tharimmune (Tharimmune) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Tharimmune Debt-to-Asset?

Tharimmune's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Tharimmune's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Tharimmune's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $8.89 Mil. Tharimmune's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

Tharimmune Debt-to-Asset Historical Data

The historical data trend for Tharimmune's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tharimmune Debt-to-Asset Chart

Tharimmune Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

23.51

6.27

3.48

Tharimmune Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial												0.12	-	-	-	-

Competitive Comparison of Tharimmune's Debt-to-Asset

For the Biotechnology subindustry, Tharimmune's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tharimmune's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tharimmune's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Tharimmune's Debt-to-Asset falls into.

Tharimmune Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Tharimmune's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	10.946
	=	0.00

Tharimmune's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	8.887
	=	0.00

Tharimmune (NAS:THAR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Tharimmune Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Tharimmune's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Tharimmune (Tharimmune) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tharimmune Inc (NAS:THAR) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1200 Route 22 East, Suite 2000, Bridgewater, NJ, USA, 08807

Website

https://www.hillstreambio.com

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors.

Executives

Randy Milby	director, officer: Chief Executive Officer	5 JACK LANE, NEWARK DE 19711
Kelly Anderson	director	C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
Leonard L Mazur	director	C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Sandeep Laumas	10 percent owner	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Thomas Hess	officer: Chief Financial Officer	366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Sireesh Appajosyula	director	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Lynne A. Bui	director	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Surender Kharbanda	10 percent owner	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Highpoint Pharmaceuticals Llc	10 percent owner	16192 COASTAL HIGHWAY, LEWES DE 19958
Kufe Llc	10 percent owner	179 GROVE STREET, WELLESLEY MA 02482
Varinder Kaur	10 percent owner	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807